Free tool
FAERS Monitor: Avmapki Fakzynja CO-Pack (Copackaged)
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 219616 or its brand name (Avmapki Fakzynja CO-Pack (Copackaged), Avutometinib Potassium, Defactinib Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
1,125
Serious
175
16% of reports
Hospitalization
123
Death reported
37
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use191
- fatigue168
- nausea156
- diarrhoea119
- rash116
- product dose omission issue99
- vomiting79
- vision blurred67
- peripheral swelling66
- acne57
- pruritus54
- dry skin46
- dizziness42
- constipation40
- disease progression38
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2025 | 288 |
| 2026 | 837 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,034 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| acneSignal | 57 | 14.1 | 10.9 | 681 |
| vision blurredSignal | 67 | 9.1 | 7.2 | 480 |
| peripheral swellingSignal | 66 | 8.0 | 6.3 | 401 |
| dry skinSignal | 46 | 6.4 | 4.9 | 207 |
| product dose omission issueSignal | 99 | 6.3 | 5.2 | 442 |
| disease progressionSignal | 38 | 6.0 | 4.4 | 154 |
| rashSignal | 116 | 5.0 | 4.2 | 372 |
| off label useSignal | 191 | 4.1 | 3.6 | 460 |
| fatigueSignal | 168 | 4.0 | 3.5 | 395 |
| nauseaSignal | 156 | 3.7 | 3.2 | 314 |
| diarrhoeaSignal | 119 | 3.4 | 2.9 | 211 |
| constipationSignal | 40 | 3.4 | 2.5 | 67 |
| vomitingSignal | 79 | 3.1 | 2.5 | 116 |
| pruritusSignal | 54 | 2.6 | 2.0 | 54 |
| dizziness | 42 | 1.6 | 1.2 | 8 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.